Aurobindo Pharma gets USFDA approval for its Cefpodoxime oral suspension

Aurobindo Pharma Ltd has announced that the USFDA has approved one more of its cephalosporins. This time it is from its third generation range. Cefpodoxime proxetil for oral suspension in the strengths of 50mg/5ml and 100mg/5ml has been approved. This is the 6th cephalosporin approval for the Company. With this the Company has representation in each of the first three generations of cephalosporin antibiotics. Cefpodoxime is the generic version of Pharmacia Upjohn's Vantin.

Cefpodoxime is mostly used to treat Acute otitis media, community acquired Pneumoniae, Uncomplicated Urinary tract infections and also skin infections. The Company is the proven leader in this segment/product range in several markets in the world. This would be an interesting niche opportunity for the Company as there are limited number of players in the segment.

The stock was trading at Rs.731.70, up by Rs.11.70 or 1.63%. The stock hit an intraday high of Rs.735 and low of Rs.722. The total traded quantity was 37792 compared to 2 week average of 182397.

Source : Equity Bulls

Keywords